Cipher Pharmaceuticals (CPHRF)
OTHER OTC:CPHRF
CPHRF Stock Chart & Stats
$10.87
-$0.10(-0.92%)
At close: 4:00 PM EST
$10.87
-$0.10(-0.92%)
Day’s Range― - ―
52-Week Range$6.63 - $12.70
Previous CloseN/A
Volume27.53K
Average Volume (3M)13.12K
Market Cap
$315.05M
Enterprise Value$314.63M
Total Cash (Recent Filing)$7.48M
Total Debt (Recent Filing)$5.49M
Price to Earnings (P/E)10.1
Beta0.13
Next Earnings
May 07, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding25,281,181
10 Day Avg. Volume17,096
30 Day Avg. Volume13,121
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.21
Enterprise Value/Gross Profit8.12
Enterprise Value/Ebitda14.22
Forecast
1Y Price Target
$15.32Price Target Upside40.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.46
Revenue Forecast (FY)$39.23M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent, growing operating and free cash flow supports durable self‑funding for operations, debt reduction, and selective business development. High cash conversion reduces refinancing risk, enables sustained investment in commercialization and margin-supporting initiatives over the next 2–6 months.
Accelerating Revenue GrowthMarked top-line acceleration indicates successful commercialization and portfolio scaling, improving fixed-cost absorption and structural margin potential. If sustained, this revenue momentum strengthens long‑run operating leverage and funds reinvestment or licensing expansion over a multi‑quarter horizon.
High-margin Flagship Product & DeleveragingA high‑margin core product that drives disproportionate EBITDA improves cash generation and strategic optionality. Strong Natroba margins enabled meaningful revolver paydown, demonstrating management's ability to convert product-level profitability into durable capital structure improvement and reinvestment capacity.
Bears Say
Volatile Profit MetricsMaterial swings in net income and profit metrics reduce the predictability of earnings and cash flow planning. This volatility complicates forecasting, capital allocation, and the ability to sustainably commit to recurring investments or dividend policies over coming quarters without clearer earnings consistency.
Declining Licensing Revenue / Absorica WeaknessSharp, multi‑period declines in licensing income and erosion of a legacy royalty asset indicate structural pressure from generics and lower royalty rates. Loss of this diversified revenue increases reliance on newer products and raises execution risk for sustaining consolidated revenue and margins.
Balance Sheet Instability SignalA pronounced leverage spike followed by rapid deleveraging signals episodic financing needs or volatility in cash flows. Such swings can constrain strategic flexibility, increase refinancing risk in stress periods, and require management attention to maintain stable access to capital across multiple quarters.
Cipher Pharmaceuticals News
CPHRF FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was $6.63 and its highest was $12.70 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is $315.05M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 38 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on Mar 12, 2026. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.155 by $0.355.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,281,181 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of $0.51 in its last earnings report, beating expectations of $0.155. Following the earnings report the stock price went up 15.297%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in CPHRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.32 (40.92% Upside)
$15.32 (40.92% Upside)
Insider Transactions
Sold Shares
Worth C$129.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.52%
12-Months-Change
Fundamentals
Return on Equity
24.23%
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
CPHRF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all CPHRF earnings summariesCPHRF Stock 12 Month Forecast
Average Price Target
$15.32
▲(40.92% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Ownership Overview
42.58% Insiders
0.94% Mutual Funds
2.60% Other Institutional Investors
53.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---